Tumor cell proliferation pathway

The term **\"tumor cell proliferation pathway\"** does not refer to a single, well-defined molecular entity or canonical therapeutic target. Instead, it describes a broad set of interconnected cellular signaling cascades and regulatory pathways that promote the division and growth of cancer cells. Key molecular components often implicated include growth factor receptors (such as the ErbB family), intracellular kinases (like PI3K, AKT, mTOR, MAPK), cell cycle regulators (including cyclins and cyclin-dependent kinases), and downstream transcription factors (such as MYC and JUNB)[2][4][1]. These pathways collectively regulate processes essential for tumor growth, survival, and resistance to therapies. While many specific molecules within these pathways are validated therapeutic targets, \"tumor cell proliferation pathway\" as named is too broad and not a standalone molecular target. Drugs aimed at halting cancer progression typically act by inhibiting one or several key molecules within these interconnected pathways, not by targeting the entire pathway[4][2][1]. The term should be replaced with more specific names of validated targets (e.g., \"Epidermal growth factor receptor\", \"Phosphatidylinositol 3-kinase\", \"Cyclin-dependent kinase 4/6\") for structured data and therapy selection.

Other names

Cell proliferation pathwayCancer cell proliferation pathwayCell cycle pathway in tumor